Objective: This study is carried out to find out efficacy of ormeloxifene in the treatment of Adenomyosis.
Study design: Prospective study conducted on the patients attending outpatient department of a tertiary health care institute in Maharashtra.
Study duration: 4 Months.
Materials and Methods: Patients in reproductive age group with symptoms suggestive of and are ultrasonographically confirmed with adenomyosis were given Tab ormeloxifene according to standard dose after initial assessment. These patients were followed after 3 months of treatment and earlier if required and assessment of success of treatment done on the basis of relief of symptoms. If the patients still complains of the symptoms Laparoscopic hysterectomy done as the ultimate line of management. The data was analyzed using simple charts and tables.
Results: The average age of occurrence of adenomyosis in our institute is 38.5 years. Most commonly they presented with the symptoms of dysmenorrhea (62.50%) others were menorrhagia and polymenorrhea. There is significant reduction in the symptoms of adenomyosis with ormeloxifene. With minor side effects like nausea, headache and oligomenorrhoea which is ultimately beneficial to the patients.
Almost 83.33% patients improved symptomatically with its use. Only 16.67% patients were not relieved of symptoms and required hysterectomy as the ultimate line of management.
Conclusion: The results of our study suggest that ormeloxifene is a promising conservative treatment for adenomyosis with minimal side effects provided the patients chosen wisely. However long term effects and side effects needs to be evaluated.